My colleague Damian Garde set up the start of big-cap biotech earnings season with a nifty Game of Thrones reference. There are six big-cap biotechs and seven great houses of Westeros. Just sayin’ …
Three key story lines for Tuesday morning’s Biogen earnings report:
1) How stable are Tecfidera sales following a period of slowing growth? The consensus U.S. sales forecast for Biogen’s key multiple sclerosis drug is $818 million, a 5 percent increase year over year, or essentially flat when price increase is factored in. A related question: How is the commercial launch of Roche’s MS drug Ocrevus impacting Biogen’s multiple sclerosis business?
About the Author Reprints
